Reacta Biotech Company
Reacta Biotech develops, manufactures and commercialises oral food challenge materials to pharmaceutical standards of Good Manufacturing Practice (GMP); provides pharmaceutical quality oral food challenges for clinical trials of novel therapies; gains regulatory approval of oral food challenge materials in various jurisdictions to enable commercial sales; provides a gold standard for clinical food allergy testing. Reacta Biotech partners with clients to provide optimal service and product solutions. The company's first product will be an oral food challenge kit for the confirmation of peanut allergy. Its proprietary technology consists of a stable food matrix prepared in a standardised process to the highest food and pharmaceutical manufacturing control standards. Through collaboration with the Manchester Institute of Biotechnology, Reacta Biotech has access to state-of-the-art analyses to profile allergen molecules in allergenic food ingredients and verify allergen doses in challenge meals.
Industry:
PharmTech
Headquarters:
Manchester, United Kingdom
Founded Date:
2013
Employees Number:
1-10
Investors Number:
2
Total Funding:
£1 250 000
Estimated Revenue:
£613 000
Last Funding Date:
04-21-020
Last Funding Type:
Venture - Series Unknown
Register and Claim Ownership